Safety and side effects of TCX regimen for the treatment of late-stage gastric cancer at Hanoi Oncology Hospital

https://doi.org/10.52322/jocmbmh.121.14

Abstract

Objectives: To evaluate the safety and side effects of TCX regimen for the treatment of late-stage gastric cancer at Hanoi Oncology Hospital from 2016 to 2019.

Material and Methods: We conducted an uncontrolled clinical intervention study on 71 patients with late-stage gastric cancer who were treated with TCX chemotherapy at Hanoi Oncology Hospital from January 2016 to the end of December 2019. Adverse effects were recorded before each subsequent course of chemotherapy based on clinical symptoms (vomiting, nausea, gastrointestinal and peripheral nervous system) and laboratory tests (hematology, liver function, kidney function).

Results: Side effects on the hematopoietic system, including erythrocytopenia (52.1%, grade 3-4 was 1.5%), leukopenia (27.2%, grade 3-4 was 1.5%), thrombocytopenia (2.5%, grade 3-4 was 0.2%). Side effects on the liver function, including SGOT elevated (13%, grade 3 was 1.0%), SGPT elevated (9.2%, grade 3 was 0.7%). No grade 4 elevation of liver enzymes. Side effects on kidney was 3%, no grade 3-4. Side effects on the digestive system including nausea (33.8%, grade 3-4 was 4%); vomiting (23.6%, grade 3-4 was 0.7%; and diarrhea (12.9%, grade 3-4 was 1.0%). Side effects of hand and foot syndrome were 40.8% (grade 3-4 was 1.0%). Peripheral nerve side effects were 41.5% (grade 3-4 was 1.7%). 

Conclusion: TCX regimen showed good outcomes in treating for patients with late-stage gastric cancer at Hanoi Oncology Hospital.